Replies to post #246817 on Amarin Corp Plc (AMRN)

[bfost]

JL -

I believe most clinicians have some familiarity with V

I have no hard data but I will take a guess based on my personal clinical experience in the primary care world.

Primary care docs:
25-40% are familiar with V
10% have ever prescribed V

Cardiologists
80% are familiar with V
40% have ever prescribed V

Endocrinologists may be in between the above 2.

This is JMO without data - I would be interested in the experiences of other docs on this board.

[Relic]

JL - Did not mean to put words in your mouth. I just feel that with the lack of sales and advertising "if generics win" will slow growth "3-5 Times as much". I run a small 100 employee company. I know that I don't put sales force and advertising in areas that have diluted supply and rock bottom prices. This would lead to a bust.

"if they lose" I think AMRN will pull advertising and layoff sales force in US very quickly which in turn will slow growth. I would say the most sales that will be done after that will be word of mouth and healthcare conferences. I think a win by generics is highly unlikely, but after the verdict we will all have the sun to our back. JMO